Samit Shah, MD
Advanced Heart Failure and Transplant Cardiology · Manhasset, NYNPI 1003040254
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $9,750 of the $12,458 with a category attached, or 78.3%. Abbott accounts for 95.3% of it on its own, with 7 other manufacturers making up the rest. 2025 is the largest year on record at $10,399, more than ten times the $211 reported in 2019.
Across 38 payments — averaging $327.83 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Abbott$12K
- Alnylam Pharmaceuticals Inc.$190
- Cvrx, Inc.$143
- Boston Scientific$120
- Impulse Dynamics (USA) Inc.$43
- Medtronic$36
- plus $49 from 2 others
What the payments were for
- Consulting fees$9,75078%
- Travel & lodging$5114%
- Food & beverage$2,19718%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Abbott | 24 | $11,878 |
| Alnylam Pharmaceuticals Inc. | 4 | $190 |
| Cvrx, Inc. | 1 | $143 |
| Boston Scientific | 3 | $120 |
| Impulse Dynamics (USA) Inc. | 1 | $43 |
| Medtronic | 2 | $36 |
| E.r. Squibb & Sons, L.L.C. | 2 | $27 |
| Bayer | 1 | $22 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$12,458 in reported general payments places this provider in the 70th percentile of 106 advanced heart failure and transplant cardiology providers in New York.
See all advanced heart failure and transplant cardiology providers in New York →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EntrestoSacubitril/Valsartan | 164 | $185,745 |
| FarxigaDapagliflozin Propanediol | 80 | $80,170 |
| EliquisApixaban | 55 | $49,986 |
| VerquvoVericiguat | 18 | $23,864 |
| JardianceEmpagliflozin | 19 | $15,729 |
| Metoprolol Succinate | 154 | $3,776 |
| Bumetanide | 59 | $3,118 |
| Isosorbide Dinitrate | 17 | $1,559 |
| Spironolactone | 163 | $1,187 |
| Torsemide | 41 | $1,053 |
| Hydralazine Hcl | 78 | $951 |
| Atorvastatin Calcium | 90 | $923 |
| Rosuvastatin Calcium | 34 | $638 |
| Amiodarone Hcl | 33 | $495 |
| Carvedilol | 56 | $446 |
Paid to pharmacies, not to this prescriber.
Other advanced heart failure and transplant cardiology in Manhasset
- Sirish VullagantiManhasset$6K
- Johanna ContrerasNew York$534K
- Scott FeitellRochester$422K
- Sean PinneyNew York$305K
- Mathew MaurerNew York$249K
- Gregg LanierHawthorne$239K
- Michelle BloomMineola$166K
- Norbert MoskovitsBrooklyn$159K
- Stephen PanValhalla$159K
- Dor LotanNew York$158K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.